Analysts have clear opinions on MYOK.

There are 7 analysts on the Wall offering 12 month price targets for MyoKardia in the last 3 months. The average price target is $85.83 with a high forecast of $104.00 and a low forecast of $76.00. The average price target represents a 90.69% increase from the last price of $45.01.
MyoKardia, Inc. (MYOK) is followed by 7 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does MyoKardia, Inc.(MYOK) do ?
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.

MyoKardia, Inc. (MYOK) Insider Trades

Multiple company employees have indulged in significant insider trading. MyoKardia, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Pres, CEO, Gianakakos Anastasios : S – Sale(-$322,246) of MYOK in the trading session of 2020-03-02.

Pres, CEO Gianakakos Anastasios : S – Sale+OE(-$142,700) of MYOK in the trading session of 2018-05-04.

Pres, CEO Gianakakos Anastasios : S – Sale(-$346,821) of MyoKardia, Inc. in the trading session of 2020-02-03.

Looking for stocks just like MYOK?

Based on Wall Street analyst research, several stocks are similar to MYOK
They are:
– EHC [Info can be found here: ]
– SEM [Info can be found here: ]